Posts Tagged ‘Pharma’
Nasodine COVID-19 Trial Concludes Recruitment – Results in June 2023
Firebrick Pharma is pleased to announce that its Phase 2 COVID-19 trial of Nasodine® Nasal Spray has closed for recruitment.
Firebrick Pharma’s Phase 3 Trial of Nasodine Resumes
Two clinical sites in Australia are now open for recruitment and three sites in South Africa will be open in the next week.
Firebrick pursues development of Nasodine for use in children
Firebrick Pharma is pleased to announce that the Paediatric Investigation Plan (PIP) for Nasodine Nasal Spray has been filed with the European Medicines Agency (EMA) Paediatric Committee (PDCO), in preparation for filing for marketing approval of Nasodine in Europe later this year. A Paediatric Investigation Plan or ‘PIP’ is a development plan aimed at ensuring…
Nasodine research points to potential role in CRS
We are pleased to announce the publication of new research into Nasodine ® Nasal Spray (“Nasodine”) identifying its potential in the management of chronic rhinosinusitis (CRS). Sponsored by Firebrick, the research was conducted at the University of Auckland and has now been published in the prestigious journal, The Laryngoscope1. “To date, the development of Nasodine…
Firebrick’s international trial gets radio spotlight
Executive Chairman Peter Molloy speaks with 3BA Radio about Firebrick’s international trial targeting the common cold.
Nasodine composition patent accepted in Australia
Firebrick Pharma Limited is pleased to announce that a patent covering the unique formulation of Nasodine® Nasal Spray has been accepted in Australia.
Update on Nasodine Phase 3 trial
Firebrick Pharma is pleased to provide an update on our Phase 3 clinical trial of Nasodine® Nasal Spray in the treatment of the common cold. As at 31 October, the trial has so far successfully recruited 224 subjects with early-stage colds into the ITT (‘Intent-To-Treat’ population), with an estimated 100 qualifying for the primary endpoint…
Firebrick announces formation of Scientific Advisory Board
Firebrick appoints four inaugural members to SAB Esteemed international panel with a wealth of medical and scientific experience SAB chaired by one of Australia’s leading virologists, Dr Simon Tucker We are pleased to announce the formation of a Scientific Advisory Board (SAB) to guide the Company’s research and development initiatives, including current new product development…
Nasodine Phase 3 common cold trial underway
Firebrick Pharma is pleased to announce that the first patient has been recruited into its confirmatory Phase 3 trial for Nasodine® Nasal Spray (“Nasodine”) as a treatment for the common cold. The randomised controlled Phase 3 trial expects to recruit up to 450 adult subjects with early cold symptoms to achieve a target treatment population…